Quince Therapeutics (QNCX) Change in Accured Expenses (2018 - 2026)

Quince Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at $701000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 70200.0% year-over-year to $701000.0; the TTM figure through Mar 2026 stood at $1.4 million (up 195.3% YoY), while the FY2025 annual figure was $742000.0, up 580.73% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $701000.0, up from $270000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 million in Q2 2025, with the low at -$2.9 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$290000.0 (2022), against an average of -$416470.6.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses plunged 278.07% in 2022, then surged 70200.0% in 2026.
• Quince Therapeutics' Change in Accured Expenses stood at -$1.4 million in 2022, then decreased by 2.95% to -$1.4 million in 2023, then soared by 69.7% to -$423000.0 in 2024, then surged by 163.83% to $270000.0 in 2025, then soared by 159.63% to $701000.0 in 2026.
• Business Quant data shows QNCX's Change in Accured Expenses at $701000.0 in Q1 2026, $270000.0 in Q4 2025, and -$604000.0 in Q3 2025.